Eton Pharmaceuticals, Inc. announced that it has entered into agreements to issue and sell 1,287,500 shares of common stock at a price of $3.50 per share for gross proceeds of $4,506,250 and to issue pre-funded warrants to purchase an aggregate of 2,462,500 shares of common stock at a price of $3.50 per share for gross proceeds of $8,618,750 for the aggregate gross proceeds of $13,125,000 on April 15, 2024. The Company also entered into an agreement to expand its existing credit facility by $21.9 million to $27.0 million and in connection therewith agreed to issue a warrant to the lender for up to 358,976 shares of common stock at a price of $3.66 per share
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.29 USD | -0.90% |
|
-1.50% | -24.89% |
05-09 | Transcript : Eton Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
05-09 | Eton Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.89% | 84.52M | |
+7.39% | 72.09B | |
+15.93% | 9.05B | |
-22.81% | 4.4B | |
+17.59% | 4.39B | |
+25.93% | 3.94B | |
+4.64% | 2.1B | |
+9.09% | 1.97B | |
-36.86% | 1.87B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- ETON Stock
- News Eton Pharmaceuticals, Inc.
- Eton Pharmaceuticals, Inc. announced that it expects to receive $13.125 million in funding